Lipid News

Unexpected roles of lipid kinases

Kaoru Goto Toshiaki Tanaka
By Kaoru Goto and Toshiaki Tanaka
November 01, 2018

Phospholipids are not mere structural components of animal cell membranes. Many of their metabolites are physiologically functional and are pivotal in intracellular signaling. Of those, diacylglycerol, or DAG, is a second messenger activating proteins containing a C1 domain, such as protein kinase C.

Evidence shows that phorbol esters, synthetic functional analogues of DAG, constitutively activate signal transduction pathways that lead to tumor formation. Thus, normal cells must regulate DAG levels within the physiological range. DAG kinases, or DGKs, are the key enzymes that regulate DAG levels. DGK phosphorylates DAG to phosphatidic acid, another lipid messenger molecule. DGKs are thought to be involved in the balanced control of these two lipid messenger signaling systems.

Functional implications of DGK-zeta in p53 regulation: Nuclear DGK-zeta modulates p53 transcriptional activity; cytoplasmic DGK-zeta facilitates p53 protein degradation.Courtesy of Kaoru Goto

DGKs differ in their molecular structure, enzymatic activity, subcellular localization and binding partners. One DGK, DGK-zeta, contains both a nuclear localization signal and nuclear export signal (1), suggesting a shuttling between the nucleus and the cytoplasm. Morphological studies on animal tissues report that DGK-zeta predominantly localizes to the nucleus in some cell types, while it exhibits both nuclear and cytoplasmic localization in others. DGK-zeta translocates from the nucleus to the cytoplasm in hippocampal neurons under stress conditions such as transient ischemia and seizures, and appears to be involved in stress responses.

What roles are assigned to DGK-zeta in the nucleus and the cytoplasm? Current data suggest that nucleocytoplasmic shuttling of DGK-zeta in neurons has a dual effect: While decreased levels of nuclear DGK-zeta lead to suppression of p53 transcriptional activity, increased levels of cytoplasmic DGK-zeta facilitate p53 protein degradation. Recent studies reveal that DGK-zeta associates with p53, and DGK-zeta deletion suppresses p53 transcriptional activity under basal and DNA-damage conditions (2). DGK-zeta association with p53 facilitates cytoplasmic degradation of p53 through the ubiquitin proteasome system, or UPS. DGK-zeta deficiency, therefore, results in increased p53 levels. Another study showed that DGK-zeta is degraded after cytoplasmic translocation in neurons, leading to increased levels of p53 protein and aberrant cell cycle reentry. In all, the levels of cytoplasmic DGK-zeta may serve as a supressor for p53 by facilitating its degradation, thus suppressing its cytotoxic effects.

What are the potential effects of DGK-zeta on other transcription factors? Nuclear factor kappa-light-chain-enhancer of activated B cells, or NF-kappaB, for example, is important in numerous biological processes, particularly immune response. A recent study showed that DGK-zeta knockdown enhances the NF-kappaB pathway in response to inflammatory cytokines. DGK-zeta downregulation accelerates phosphorylation of the p65 subunit and its nuclear translocation, increasing NF-kappaB transactivation activity. These reports suggest that DGK-zeta exerts a regulatory effect on p53 and NF-kappaB (3).

A key question is determining the molecular mechanisms exerted by DGK-zeta on p53 and NF-kappaB. We want to know whether DGK-zeta catalytic activity, which alters the balance of DAG and phosphatidic acid in the nucleus and cytoplasm, is essential. How DGK activity modulates transcriptional activities is not known, but it turns out that p53 degradation mediated through cytoplasmic DGK-zeta and UPS is not kinase activity–dependent. We have found unexpected roles of DGK-zeta on transcription factors; there is much to learn about how lipid-metabolizing enzymes impact cellular signaling involved in transcriptional regulation.

References

1. Goto, K. & Kondo, H. Proc. Natl. Acad. Sci. USA.93, 11196-11201 (1996).
2. Tanaka, T. et al. J. Cell Sci.126, 2785-2797 (2013).
3. Tanaka, T. et al. Adv. Biol. Regul.60, 15-21 (2016).

Kaoru Goto
Kaoru Goto

Kaoru Goto is a professor in the department of anatomy and cell biology, Yamagata University School of Medicine.

Toshiaki Tanaka
Toshiaki Tanaka

Toshiaki Tanaka is an assistant professor in the department of anatomy and cell biology, Yamagata University School of Medicine.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Life's little oscillations
News

Life's little oscillations

April 05, 2020

Concentrations of molecules rise and fall, genes switch on and off, and circadian clocks keep time. These biochemical fluctuations are crucial for myriad biological needs, and cells couldn't function without them.

A small trial finds that hydroxychloroquine is not effective for treating coronavirus
News

A small trial finds that hydroxychloroquine is not effective for treating coronavirus

April 05, 2020

Despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney
Journal News

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney

April 03, 2020

In the inaugural JBC Methods Madness Tournament, cryo­–EM/ET gave structural biologists around the world something to cheer about, beating mass spectrometry 51% to 49% —​ a margin thinner than shaved ice. 

A small army of researchers races to build a coronavirus interactome
News

A small army of researchers races to build a coronavirus interactome

April 01, 2020

Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.

Parkinson's  Awareness Month
Health Observance

Parkinson's Awareness Month

April 01, 2020

It is the second-most common progressive neurodegenerative disease, occurring in 1% of people over the age of 60 and in 5% of people over 85.

Multiomics meets antimalarials
Journal News

Multiomics meets antimalarials

March 31, 2020

Researchers in Australia use an innovative multiomics approach to analyze a new drug against malaria parasites.